[Clinical evaluation of ciprofloxacin on biliary tract infection following oral administration].
A newly synthesized antibiotic of quinoline carboxylic acid group, ciprofloxacin (BAY o 9867, CPFX) for oral administration, has a broad spectrum and high antibacterial activity against various bacterial species including aerobic and anaerobic bacteria such as P. aeruginosa and B. fragilis. The CPFX was administered orally in a dose of 200 mg 3 times daily for 5 to 8 days (6.3 +/- 1.0 days) to 12 patients with biliary tract infection consisting of 2 males and 10 females. Two of them were outpatients and 10 were hospitalized. Ages ranged from 27 to 72 years (mean 51.8 +/- 14.8 years), weights from 48.5 to 73.5 kg (mean 60.5 +/- 7.7 kg). All cases were complicated with cholecystolithiasis, with 4 acute and 8 subacute cases. Organisms isolated before the initiation of the CPFX treatment included 3 strains of E. coli from ERCP bile of 3 cases. Infected bacteria were eradicated in 3 cases but results were unknown in the other 9 cases. Clinical responses were excellent in 2 cases, good in 8 cases, fair in 1 case and poor in 1 case. No adverse effect was recognized. Therefore, CPFX appears to be a very useful drug when used for chemotherapy of biliary tract infectious diseases.
D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002764:Cholecystitis / Q000188:drug therapy* / Q000378:metabolism; D002769:Cholelithiasis / Q000150:complications; D002939:Ciprofloxacin / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged
D002939:Ciprofloxacin